The Genetics of Alzheimer Disease
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Family history is the second strongest risk factor for Alzheimer disease (AD) following advanced age.Twin and family studies indicate that genetic factors are estimated to play a role in at least 80% of AD cases.The inheritance of AD exhibits a dichotomous pattern.On one hand, rare mutations in APP, PSEN1, and PSEN2 virtually guarantee early-onset (,60 years) familial AD, which represents 5% of AD.On the other hand, common gene polymorphisms, such as the 14 and 12 variants of the APOE gene, can influence susceptibility for 50% of the common late-onset AD.These four genes account for 30% -50% of the inheritability of AD.Genome-wide association studies have recently led to the identification of 11 additional AD candidate genes.This paper reviews the past, present, and future attempts to elucidate the complex and heterogeneous genetic underpinnings of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, 228 PSEN1 mutations have been identified causing ADAD (49, 303, 304, 440, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“CLU gene encodes clusterin or APOJ that besides its functions in lipid transport, membrane recycling, cell adhesion, and apoptosis (90, 444, 600, 677) affects transvascular A 𝛃 clearance by promoting A 𝛃 42 efflux across the BBB (580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PSEN1 mutations lead to faster soluble-to-fibrillar conversion of A 𝛃 42 promoting amyloid deposition in the brain (303, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Autosomal-dominant AD (ADAD) is an inherited form of AD caused by mutations in amyloid precursor protein ( APP ) and presenilin-1 and 2 ( PSEN1; PSEN2 ) genes (49, 177, 303, 304, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the major genetic risk factor for sporadic, late-onset AD (199, 368, 580, 612).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 3×
“Goate et al. (1991), then resequenced the same two APP exons to reveal the first EO-FAD mutation (London mutation; V717I) in APP.”
BackgroundThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“In 1987, we as well as others isolated the amyloid b (A4) protein precursor (APP; Goldgaber et al. 1987; Kang et al. 1987; Tanzi et al. 1987a, 1988) and mapped it to chromosome 21.”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 3×
“1987b); they were ultimately demonstrated to carry PSEN1 mutations (Sherrington et al. 1995).”
BackgroundSelf-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 14×
“Genetic association studies remain the most common method for identifying novel LOAD genes and are most often employed in the form of large-scale GWASs that screen the entire human genome for novel disease loci.”
InfluentialScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 3×
“Whether EO-FAD mutations appear in APP near the g-secretase cleavage site or in the presenilins, the vast majority of them serve to increase the ratio of Ab42:Ab40. g-Secretase modulators are aimed at reversing this ratio and represent very promising compounds for treating and preventing AD based on what has been garn…”
BackgroundSelf-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“Shortly thereafter, we first reported a homolog of PSEN1 called presenilin (PSEN2; Levy-Lahad et al. 1995) on chromosome 1 and showed that it harbors the N141I mutation in Volga-German EO-FAD families.”
BackgroundSelf-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Research works printed but not linked: 2
- Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zis- mann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huen- telman MJ, et al. 2007. Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE 14 car- riers. Neuron 54: 713 -720.
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993. Apolipopro- tein E: High-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90: 1977-1981.
Cited by
Items 401–500 of 804
Ghrelin system in Alzheimer's disease
Tian, J., Wang, T., & Du, H. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102655 · Cited by 17
Biundo, F., Ishiwari, K., Prete, D. D., & D'adamio, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7389 · Cited by 17
Exploring the Potential of Neuroproteomics in Alzheimer's Disease
Uddin, M. S., Kabir, M. T., Jakaria, M., Sobarzo‐Sánchez, E., Barreto, G. E., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200603112030 · Cited by 17
Gene Editing and Alzheimer's Disease: Is There Light at the End of the Tunnel?
Stepanichev, M. Y. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.00004 · Cited by 18
Vorobyeva, A. G., Lee, R., Miller, S., Longen, C., Sharoni, M., Kandelwal, P. J., Kim, F. J., Marenda, D. R., & Saunders, A. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.591792 · Cited by 16
Yuan, H., Zhou, J., Li, H., Kang, S., & Park, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146698 · Cited by 16
Blood tests could soon predict your risk of Alzheimer’s
Abbott, A. (2024) · Nature · doi:10.1038/d41586-024-02535-x · Cited by 16
MacMullen, C., Sharma, N., & Davis, R. L. (2024) · Brain · doi:10.1093/brain/awae364 · Cited by 18
Synergistic reduction in interfacial flexibility of TREM2 R47H and ApoE4 may underlie AD pathology
Lietzke, E. E., Saeb, D., Aldrich, E. C., Bruce, K. D., & Sprenger, K. G. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70120 · Cited by 16
Failure analysis of clinical trials to test the amyloid hypothesis
Hyman, B. T., & Sorger, P. K. (2014) · Annals of Neurology · doi:10.1002/ana.24227 · Cited by 16
Roussotte, F. F., Daianu, M., Jahanshad, N., Leonardo, C. D., & Thompson, P. M. (2013) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9263-y · Cited by 18
Targeting ubiquilin-1 in Alzheimer's disease
Takalo, M., Haapasalo, A., Natunen, T., Viswanathan, J., Kurkinen, K. M. A., Tanzi, R. E., Soininen, H. S., & Hiltunen, M. O. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.791284 · Cited by 18
Self-citationRobust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
Fernández‐Martínez, J. L., Álvarez-Machancoses, Ó., deAndrés‐Galiana, E. J., Bea, G., & Kloczkowski, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103594 · Cited by 18
The impact of ageing on lipid-mediated regulation of adult stem cell behavior and tissue homeostasis
Demarco, R. S., Clémot, M., & Jones, D. L. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111278 · Cited by 18
Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease
Caldwell, A. B., Liu, Q., Zhang, C. M., Schroth, G. P., Galasko, D. R., Rynearson, K. D., Tanzi, R. E., Yuan, S. H., Wagner, S. L., & Subramaniam, S. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12553 · Cited by 16
Self-citationModulation of Aβ42 in vivo by γ-secretase modulator in primates and humans
Ling, I., Golde, T. E., Galasko, D. R., & Koo, E. H. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0137-y · Cited by 17
Kumar, S., Kapadia, A., Theil, S., Joshi, P., Riffel, F., Heneka, M. T., & Walter, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.619639 · Cited by 18
Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models
Gurdon, B., & Kaczorowski, C. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105558 · Cited by 17
Kim, D., Basile, A. O., Bang, L., Horgusluoglu, E., Lee, S., Ritchie, M. D., Saykin, A. J., & Nho, K. T. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0454-0 · Cited by 16
Mate, V., Smolek, T., Kazmerova, Z., Jadhav, S., Brezováková, V., Jurkanin, B., Uhrinova, I., Basheer, N., Žilka, N., Katina, S., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.935973 · Cited by 15
Vascular Function and Ion Channels in Alzheimer's Disease
Taylor, J. L., Baudel, M. A. S. M., Nieves‐Cintrón, M., & Navedo, M. F. (2024) · Microcirculation · doi:10.1111/micc.12881 · Cited by 15
RNA‐Based Therapies for Neurodegenerative Diseases Targeting Pathogenic Proteins
Rabbani, S. A., El‐Tanani, M., Sharma, S., El‐Tanani, Y., Kumar, R., Saini, M., Yadav, M., Khan, M. A., & Parvez, S. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70110 · Cited by 16
Cahill, L. S., Cameron, J. M., Winterburn, J. L., Macos, P., Hoggarth, J., Dzamba, M., Brudno, M., Nutter, L. M. J., Sproule, T. J., Burgess, R. W., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0013-20.2020 · Cited by 17
Importance of γ-secretase in the regulation of liver X receptor and cellular lipid metabolism
Gutierrez, E., Lütjohann, D., Kerksiek, A., Fabiano, M., Oikawa, N., Kuerschner, L., Thiele, C., & Walter, J. (2020) · Life Science Alliance · doi:10.26508/lsa.201900521 · Cited by 16
Lithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice Model of Alzheimer’s Disease
Gherardelli, C., Cisternas, P., & Inestrosa, N. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158733 · Cited by 16
Macchi, B., Marino‐Merlo, F., Frezza, C., Cuzzocrea, S., & Mastino, A. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8641-9 · Cited by 17
Brain atrophy rates in first degree relatives at risk for Alzheimer's
Lampert, E. J., Choudhury, K. R., Hostage, C. A., Rathakrishnan, B., Weiner, M. W., Petrella, J. R., & Doraiswamy, P. M. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.08.024 · Cited by 15
Current concepts in Alzheimer’s Disease: molecules, models and translational perspectives
Rutten, B. P. F., & Steinbusch, H. W. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-33 · Cited by 15
Xicota, L., Cosentino, S., Vardarajan, B. N., Mayeux, R. P., Perls, T. T., Andersen, S. L., Zmuda, J. M., Thyagarajan, B., Yashin, A. I., Wojczynski, M. K., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13718 · Cited by 14
Initiative, A. D. N., Miller, J. E., Shivakumar, M., Lee, Y., Han, S., Horgousluoglu, E., Risacher, S. L., Saykin, A. J., Nho, K. T., & Kim, D. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0390-6 · Cited by 15
Chen, S., & Zacharias, M. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.05.023 · Cited by 15
Moreno, J., Lanau, A. V., Madrigal, L., Pineda, A. Y. B., Hernandez, J. V., Campo, O., Soto-Ospina, A., Marín, P. A., Rishishwar, L., Norris, E. T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269955 · Cited by 15
Meineck, M., Schuck, F., Abdelfatah, S., Efferth, T., & Endres, K. (2016) · Medicines · doi:10.3390/medicines3040030 · Cited by 14
Mosca, A., Sperduti, S., Pop, V., Ciavardelli, D., Granzotto, A., Punzi, M., Stuppia, L., Gatta, V., Assogna, F., Banaj, N., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00092 · Cited by 15
Differentiating the dementias: a neurological approach
Shaik, S. S., & Varma, A. R. (2012) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.224 · Cited by 16
Boggs, K. N., Kakalec, P. A., Smith, M. L., Howell, S., & Flinn, J. M. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.09.021 · Cited by 14
Insulin BBB pharmacokinetics in young apoE male and female transgenic mice
Rhea, E. M., Torres, E. R. S., Raber, J., & Banks, W. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228455 · Cited by 13
Association of APOE polymorphisms and stressful life events with dementia in a Pakistani population
Chaudhry, M., Hasnain, S., Snitz, B. E., Wang, X., Rosenthal, S. L., Demirci, F. Y., & Kamboh, M. I. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.04.008 · Cited by 13
BRI2 as an anti-Alzheimer gene
Matsuda, S., & Senda, T. (2018) · Medical Molecular Morphology · doi:10.1007/s00795-018-0191-1 · Cited by 13
Signorini-Souza, I. D. L., Tureck, L. V., Batistela, M. S., de Almeida, R. C., de Almeida, S. M., Alle, L. F., & de Souza, R. L. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149090 · Cited by 12
Granov, R., Vedad, S., Wang, S.-H., Durham, A., Shah, D., & Pasinetti, G. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04339-6 · Cited by 12
Use of Quantum Dots as Nanotheranostic Agents: Emerging Applications in Rare Genetic Diseases
Neethu, K. M., Karmakar, S., Sahoo, B., Mishrra, N., & Moitra, P. (2025) · Small · doi:10.1002/smll.202407353 · Cited by 15
NLRP3 inflammasome and Alzheimer’s disease: bridging inflammation and neurodegeneration
Wasim, R., Azmi, S., Ahmad, A., & Srivastava, A. (2026) · Inflammopharmacology · doi:10.1007/s10787-025-02092-3 · Cited by 12
Sharma, S. K. (2021) · Annals of Neurosciences · doi:10.1177/09727531211009420 · Cited by 12
Genomic stress and impaired DNA repair in Alzheimer disease
Neven, J., Issayama, L. K., Dewachter, I., & Wilson, D. M. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103678 · Cited by 13
Blood–Brain Barrier Transport of Alzheimer’s Amyloid β-Peptide
Nelson, A. R., Sagare, A. P., & Zloković, B. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00009-5 · Cited by 14
Sogorb‐Esteve, A., García‐Ayllón, M., Fortea, J., Sánchez‐Valle, R., Lleó, A., Molinuevo, J. L., & Sáez‐Valero, J. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0131-2 · Cited by 12
Jamasbi, E., Hossain, M. A., Tan, M., Separovic, F., & Ciccotosto, G. D. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.01.024 · Cited by 13
Can Animal Models Inform on the Relationship between Depression and Alzheimer Disease?
Nyarko, J. N. K., Quartey, M. O., Baker, G. B., & Mousseau, D. D. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718772514 · Cited by 12
Cross-Linked Amyloid β-Protein Oligomers: A Missing Link in Alzheimer’s Disease Pathology?
Urbanc, B. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c07716 · Cited by 13
Epigenetic Modification and Its Role in Alzheimer's Disease
Zhu, Y., Feng, Y., Liu, T., & Wu, Y. (2015) · Integrative Medicine International · doi:10.1159/000437329 · Cited by 15
Sarma, M., & Chatterjee, S. (2025) · Diagnostics · doi:10.3390/diagnostics15020211 · Cited by 14
Fernandez, F., & Reeves, R. H. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_12 · Cited by 11
Karim, N., Khan, I., Khan, I., Halim, S. A., Khalid, A., Abdalla, A. N., Rehman, N. U., Khan, A., & Al‐Harrasi, A. (2023) · ACS Omega · doi:10.1021/acsomega.2c07951 · Cited by 11
Genetic, vascular and amyloid components of cerebral blood flow in a preclinical population
Padrela, B. E., Lorenzini, L., Collij, L. E., García, D. V., Coomans, E. M., Ingala, S., Tomassen, J., Deckers, Q., Shekari, M., de Geus, E. J. C., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231178993 · Cited by 13
Farfara, D., Sooliman, M., Avrahami, L., Royal, T. G., Amram, S., Rozenstein‐Tsalkovich, L., Trudler, D., Blanga‐Kanfi, S., Eldar-Finkelman, H., Pahnke, J., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02823-9 · Cited by 11
Seddon, A. R., MacArthur, C. P., Hampton, M. B., & Stevens, A. J. (2024) · Redox Report · doi:10.1080/13510002.2024.2428152 · Cited by 12
Sorting Out Presenilins in Alzheimer’s Disease
Wolfe, M. S., & Yankner, B. A. (2016) · Cell · doi:10.1016/j.cell.2016.06.034 · Cited by 13
Sun, X., Zhang, H., Yao, D., Xu, Y., Jing, Q., Cao, S., Li, T., & Li, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215232 · Cited by 13
Lin, Y., Wang, J., Wang, K., Liao, J., & Cheng, I. H.-J. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12829 · Cited by 11
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease
Huang, Y.-Y., Lin, S., Chiang, W.-Y., Chang, Y.-T., Yang, C.-C., Liao, C.-Y., Chang, Y.-L., Lin, C., & Teng, S. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01006-y · Cited by 10
Choe, K., Ahmad, R., Kang, M. H., Lee, H. J., Ahmad, S., Park, T. J., & Kim, M. O. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02485-5 · Cited by 11
Xie, X., Liu, J., Liang, W., Zhang, Y., Gong, X., Yuan, S., Qi, C., Huang, M., Shi, L., Hou, M., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.01.014 · Cited by 11
Pai, M., Lu, W., Chen, M., & Xue, B. (2023) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2023.104992 · Cited by 10
A Next-Generation Sequencing Study in a Cohort of Sicilian Patients with Parkinson’s Disease
Salemi, M., Lanza, G., Salluzzo, M. G., Schillaci, F. A., Blasi, F. D. D., Cordella, A., Caniglia, S., Lanuzza, B., Morreale, M., Marano, P., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11123118 · Cited by 11
γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer’s Disease
Johnson, D. S., & Pettersson, M. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_19 · Cited by 12
Siddarth, P., Burggren, A. C., Merrill, D. A., Ercoli, L. M., Mahmood, Z., Barrio, J. R., & Small, G. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208358 · Cited by 12
Cycle on Wheels: Is APP Key to the AppBp1 Pathway?
Chen, Y., Neve, R., Zheng, H., Griffin, W. S. T., Barger, S. W., & Mrak, R. E. (2014) · PubMed · Cited by 10
PSEN1 c.1292C<A Variant and Early-Onset Alzheimer’s Disease: A Scoping Review
Orozco-Barajas, M., Oropeza-Ruvalcaba, Y., Canales-Aguirre, A. A., & Sánchez-González, V. J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.860529 · Cited by 11
The impact of genetic risk for Alzheimer’s disease on the structural brain networks of young adults
Mirza-Davies, A., Foley, S. F., Caseras, X., Baker, E. A., Holmans, P., Escott‐Price, V., Jones, D. K., Harrison, J. R., & Messaritaki, E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.987677 · Cited by 10
A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease
Luedecke, D., Becktepe, J. S., Lehmbeck, J. T., Finckh, U., Yamamoto, R., Jahn, H., & Boelmans, K. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.02.034 · Cited by 11
DNA Methylation in Neurodegenerative Diseases
Al‐Mahdawi, S., Virmouni, S. A., & Pook, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801899-6.00020-6 · Cited by 10
Sui, X., Prado, M. A., Paulo, J. A., Gygi, S. P., Finley, D. J., & Morimoto, R. I. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.28.509812 · Cited by 10
Pereira, M. E., Souza, J. V., Gomar, G. G., Kruk, I. L., & Oliveira, C. S. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251346981 · Cited by 10
CD2AP at the junction of nephropathy and Alzheimer’s disease
Vandal, M., Janmaleki, M., Rea, I. M., Gunn, C., Hirai, S., Biernaskie, J. A., Chun, J., Gordon, G. R., Shaw, A. S., Sanati‐Nezhad, A., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00852-x · Cited by 9
Labra, S. R., Compher, J., Prabhavalkar, A., Almaraz, M., Kwong, C. C., Baal, C., Talantova, M. V., Dolatabadi, N., Piña‐Sanz, J., Wang, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.202514783 · Cited by 15
Zooming into Disease at the Nanoscale: High-Speed Atomic Force Microscopy in Biomedical Discovery
Lim, K., & Wong, R. W.-C. (2026) · ACS Nano · doi:10.1021/acsnano.5c20737 · Cited by 9
Alsaleem, M. A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Abdel‐Fattah, M. M., Alrouji, M., Al‐Harchan, N. A., Alruwaili, M., Papadakis, M., Alexiou, A. T., & Batiha, G. E. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70378 · Cited by 11
Mello-Hortega, J. V., Oliveira, C. S.-D., Araújo, V. E. S. D., Alle, L. F., Tureck, L. V., & de Souza, R. L. R. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70229 · Cited by 12
Derailed Intraneuronal Signalling Drives Pathogenesis in Sporadic and Familial Alzheimer’s Disease
Dooren, T. V., Princen, K., Witte, K. D., & Griffioen, G. (2014) · BioMed Research International · doi:10.1155/2014/167024 · Cited by 9
A lzheimer's Disease Biomarkers: More Than Molecular Diagnostics
Anderson, D. C. (2013) · Drug Development Research · doi:10.1002/ddr.21073 · Cited by 12
Endres, K., Reinhardt, S., Geladaris, A., Knies, J., Grimm, M. O. W., Hartmann, T., & Schmitt, U. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0280-9 · Cited by 10
Patient-derived iPSCs, a reliable in vitro model for the investigation of Alzheimer’s disease
Asiamah, E. A., Guo, R., Kong, D., Feng, B., He, J., Zhang, W., Liu, X., Du, X., Ma, Z., Liu, B., et al. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0065 · Cited by 10
Mesa, H., Zhang, E. Y., Wang, Y., & Zhang, Q. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30999 · Cited by 9
Chen, H.-Y., Liao, C.-Y., Li, H., Ke, Y., Lin, C., & Teng, S.-C. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae007 · Cited by 9
The Genetic Basis of Alzheimer's Disease
Hooli, B. V., & Tanzi, R. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00034-2 · Cited by 9
Self-citationA Biophysical Approach to the Identification of Novel ApoE Chemical Probes
Kraft, L., Serpell, L. C., & Atack, J. R. (2019) · Biomolecules · doi:10.3390/biom9020048 · Cited by 9
Epigenomics of Alzheimer’s Disease
Bennett, D. A., Yu, L., Yang, J., Klein, H., & Jager, P. L. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800802-7.00009-5 · Cited by 11
Vieira, R. N., de Ávila, R. T., de Paula, J. J., Cintra, M. T. G., de Souza, R. P., Nicolato, R., Malloy‐Diniz, L. F., de Miranda, D. M., de Moraes, E. N., Marco, L. A. D., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4440 · Cited by 9
Molecular neurodegeneration: basic biology and disease pathways
Vassar, R. J., & Zheng, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-34 · Cited by 9
Mitochondrial Function in Alzheimer’s Disease: Focus on Astrocytes
Lampinen, R., Belaya, I., Boccuni, I., Malm, T., & Kanninen, K. M. (2018) · Astrocyte - Physiology and Pathology · doi:10.5772/intechopen.71825 · Cited by 8
Prabhakar, V., & Liu, K. (2023) · Archives of Clinical and Biomedical Research · doi:10.26502/acbr.50170342 · Cited by 8
Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer's disease
Tremblay, C., Rahayel, S., Pastor‐Bernier, A., St‐Onge, F., Vo, A., Rheault, F., Daneault, V., Morys, F., Rajah, N., Villeneuve, S., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf099 · Cited by 9
Adji, A. S., Widjaja, J. S., Wardani, V. A. K., Muhammad, A. H., Handajani, F., Putra, H. B. P., & Rahman, F. S. (2022) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2022.9053 · Cited by 9
Bioinformatic prediction of the molecular links between Alzheimer’s disease and diabetes mellitus
Castillo-Velázquez, R., Martínez-Morales, F., Castañeda‐Delgado, J. E., García-Hernández, M. H., Herrera-Mayorga, V., Sánchez, F. A. P., Rivera, G., Rivas-Santiago, B. T., & Lara-Ramirez, E. E. (2023) · PeerJ · doi:10.7717/peerj.14738 · Cited by 10
Central Nicotinic and Muscarinic Receptors in Health and Disease
Tizabi, Y., Getachew, B., Tsytsarev, V., Csoka, A. B., Copeland, R., & Heinbockel, T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112447 · Cited by 11
Pope, C. A., Wilkins, H., Swerdlow, R. H., & Wolfe, M. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210366 · Cited by 9
Flexible N‐Termini of Amyloid β‐Protein Oligomers: A Link between Structure and Activity?
Urbanc, B. (2017) · Israel Journal of Chemistry · doi:10.1002/ijch.201600097 · Cited by 9
A Pathogenic Variant p.Phe177Val in PSEN1 Causes Early-Onset Alzheimer’s Disease in a Chinese Family
Jiang, B., Bi, M., Li, J., Liu, Q., Xiao, N., Fang, J., Shi, M.-Y., Yu, Z.-W., Ma, Q., Tong, S., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00713 · Cited by 8
Abdullah, M., Wah, Y. B., Majeed, A. B. A., Zakaria, Y., & Shaadan, N. (2022) · Pertanika journal of science & technology · doi:10.47836/pjst.30.2.19 · Cited by 10
Metadata
- Authors
- Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tanzi, R. E.
- ORCID
- Tanzi, R. E.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-07-25
- Volume
- 2
- Issue
- 10
- Pages
- a006296-a006296
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W4233829850
- Cited by
- 727
- References
- 55
- Citations by year
- 2026: 40 · 2025: 55 · 2024: 58 · 2023: 70 · 2022: 54 · 2021: 49 · 2020: 54 · 2019: 40 · 2018: 42 · 2017: 55 · 2016: 60 · 2015: 52 · 2014: 61 · 2013: 32 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, genetic susceptibility, familial Alzheimer's disease, APP mutations, presenilin 1, presenilin 2, apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, twin and family studies, genome-wide association study, candidate genes, heritability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.